- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05950984
Medical Device (MD) Derived Pharmacokinetic (PK) Parameters for Vancomycin (MD-PK) (MD-PK)
An Investigation Into How Medical Device Obtained Variables Influence the Pharmacokinetic Profile of Vancomycin: a Paediatric and Adult Critical Care Feasibility Assessment at a London Tertiary-care Hospital
Getting the right dose of antibiotic promptly is an important part of treating infections. Unfortunately, when an infection is severe (sepsis) the body changes how it processes antibiotics. Consequently, some people with severe infection retain antibiotics for too long (risking adverse effects), whilst others excrete antibiotics too quickly (risking under-treatment).
Mathematical models can help researchers understand drug handling variability (known as pharmacokinetics) between people. These models require very accurate information about drug administration and drug blood concentration timings. Researchers usually rely on someone recording these timings, but recording errors can make models inaccurate.
We would like to understand if using data from routinely used electronic drug infusion devices (recording the exact time of administration) can improve the accuracy of pharmacokinetic models. We intend to investigate this with an antibiotic (vancomycin) that clinicians already routinely monitor blood concentrations for. Adults and children treated at St George's Hospital intensive care units will be invited to participate in the study which will last for 28-days within a 14-month period. Participants will donate a small amount of extra blood and provide researchers access to their clinical data. Blood will be taken at special times during vancomycin treatment from lines placed as part of standard treatment, minimising any pain or distress. There will be no other changes to patient's treatment.
In the future, data from this study might help change the way we dose antibiotics. The National Institute for Health and Care Research and Pharmacy Research UK are supporting the study with funding.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Robert Oakley, MPharm
- Phone Number: 3685 02086721255
- Email: robert.oakley@nhs.net
Study Contact Backup
- Name: Dagan Lonsdale, MB BS, PhD
- Phone Number: 02087250205
- Email: dlonsdal@sgul.ac.uk
Study Locations
-
-
-
London, United Kingdom, SW17 0QT
- Recruiting
- St Georges University Hospitals NHS Foundation Trust
-
Contact:
- Robert Oakley, MPharm
- Phone Number: 3685 02086721255
- Email: robert.oakley@nhs.net
-
Contact:
- Dagan Lonsdale, MB BS, PhD
- Phone Number: 02087250205
- Email: dlonsdal@sgul.ac.uk
-
Principal Investigator:
- Dagan Lonsdale, MB BS, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Admitted to either adult or paediatric intensive care unit (ICU) and receiving intravenous vancomycin (continuous or intermittent infusion only), to prevent or treat a clinical infection
- Informed consent form signed by participant/parent/legal guardian/legal representative (as determined by age group/capacity, consent may be retrospective) or signed informed personal/nominated consultee declaration
- Age from 1-day since birth
Exclusion Criteria:
- Previous enrolment into this study
- Treating clinician feels participant unlikely to survive beyond 48-hours from enrolment or treatment has been withdrawn for reasons of palliation
- Absence of in-dwelling vascular access from which samples may be drawn or removal of in-dwelling access prior to retrieval of a 3rd blood sample (for assay of vancomycin concentration)
- Non-continuous renal replacement (i.e. intermittent haemodialysis/ peritoneal dialysis)
- Hypersensitivity or allergies to vancomycin, its excipients, or the infusion fluid
- Treatment outside an ICU area
In paediatrics:
- Required blood sampling exceeds 3% of total blood volume in a four-week period or 1% at any single time (European Medicines Agency, 2009)
- Where there is disagreement between child consent/assent and parental/ legal guardian consent/assent
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Critically Ill Adults and Children
Adults and children from 1-day old admitted to a critical care unit.
|
Intravenous vancomycin administration accuracy will be determined by comparing data obtained from drug infusion pumps with manually input administration times from the electronic Prescribing and Medicines Administration (ePMA) system.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Function Value
Time Frame: Within collection of 15 vancomycin serum concentrations or 28 days from first study recorded administration of vancomycin
|
Pharmacokinetic model fit determined quantitively by Objective Function Value (2.log likelihood) using vancomycin administration time data recorded by patient's bedside drug infusion devices compared to manually recorded data
|
Within collection of 15 vancomycin serum concentrations or 28 days from first study recorded administration of vancomycin
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participant Vancomycin Volume of Distribution
Time Frame: Within collection of 15 vancomycin serum concentrations or 28 days from first study recorded administration of vancomycin
|
Calculation of participant's vancomycin volume of distribution (litres) using non-linear mixed effects modelling methods from obtained non-protein bound and total vancomycin concentrations and patient's drug infusion device obtained administration time data
|
Within collection of 15 vancomycin serum concentrations or 28 days from first study recorded administration of vancomycin
|
Participant Vancomycin Clearance
Time Frame: Within collection of 15 vancomycin serum concentrations or 28 days from first study recorded administration of vancomycin
|
Calculation of participant vancomycin clearance (litres/hour) using non-linear mixed effects modelling methods using obtained non-protein bound and total vancomycin concentrations and participant's drug infusion device derived administration time data
|
Within collection of 15 vancomycin serum concentrations or 28 days from first study recorded administration of vancomycin
|
Participant 24-hour Area Under the Vancomycin Concentration Time Curve (AUC)
Time Frame: Within collection of 15 vancomycin serum concentrations or 28 days from first study recorded administration of vancomycin
|
Calculation of participant's AUC (milligrams.hour/litre)
using obtained non-protein bound and total vancomycin concentrations and participant's drug infusion device derived administration time data
|
Within collection of 15 vancomycin serum concentrations or 28 days from first study recorded administration of vancomycin
|
Participant 24-hour AUC:MIC Ratio
Time Frame: Within collection of 15 vancomycin serum concentrations or 28 days from first study recorded administration of vancomycin
|
Calculation of the area under the 24-hour non-protein bound and total vancomycin concentration AUC/bacterial minimum inhibitory concentration (MIC) ratio using an empiric MIC of 1mg/L or MIC of obtained isolates (if available) using trapezial rule or vancomycin dose and calculated clearance
|
Within collection of 15 vancomycin serum concentrations or 28 days from first study recorded administration of vancomycin
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Association Between Participant's Mean 24-hour AUC:MIC and Microbiological Cure
Time Frame: Within collection of 15 vancomycin serum concentrations or 28 days from first study recorded administration of vancomycin
|
Microbiological cure defined as eradicated baseline microorganisms and no new microorganisms are identified via bacterial cultures (if available), plus, the patient has received allocated treatment for at least 2-days with no modification or a failure
|
Within collection of 15 vancomycin serum concentrations or 28 days from first study recorded administration of vancomycin
|
Association Between Participant's Mean 24-hour AUC:MIC and Length of Intensive Care (ICU) Unit Stay
Time Frame: Within collection of 15 vancomycin serum concentrations or 28 days from first study recorded administration of vancomycin
|
ICU stay quantified by days since admission, categories include: <2 days, < 7 days, <14 days, >14 days
|
Within collection of 15 vancomycin serum concentrations or 28 days from first study recorded administration of vancomycin
|
Association Between Participant's Mean 24-hour AUC:MIC and Infection Related Mortality
Time Frame: Within collection of 15 vancomycin serum concentrations or 28 days from first study recorded administration of vancomycin
|
Cause of mortality will be derived from participant's medical notes
|
Within collection of 15 vancomycin serum concentrations or 28 days from first study recorded administration of vancomycin
|
Association Between Participant's Mean 24-hour AUC:MIC and Infection related ICU Re-admission
Time Frame: Within collection of 15 vancomycin serum concentrations or 28 days from first study recorded administration of vancomycin
|
Cause of re-admission will be derived from participant's medical notes
|
Within collection of 15 vancomycin serum concentrations or 28 days from first study recorded administration of vancomycin
|
Association Between Participant's Mean 24-hour AUC:MIC and Vancomycin Associated Acute Kidney Injury (AKI)
Time Frame: Within collection of 15 vancomycin serum concentrations or 28 days from first study recorded administration of vancomycin
|
AKI defined by Kidney Disease: Improving Global Outcomes (KDIGO) Criteria
|
Within collection of 15 vancomycin serum concentrations or 28 days from first study recorded administration of vancomycin
|
Association Between Participant's Mean 24-hour AUC:MIC and Adult National Early Warning Score (NEWS2) or Paediatric Early Warning Score (PEWS3)
Time Frame: Within collection of 15 vancomycin serum concentrations or 28 days from first study recorded administration of vancomycin
|
Warning scores calculated on day of (and closest to) first dose of study recorded vancomycin treatment course, between 2-3 days since vancomycin course initiation and at end of vancomycin course or 28 days from first study recorded administration of vancomycin
|
Within collection of 15 vancomycin serum concentrations or 28 days from first study recorded administration of vancomycin
|
Collaborators and Investigators
Collaborators
Publications and helpful links
General Publications
- Oakley R, Bakrania P, Yau T, Standing J, Lonsdale D. Variable adherence to and effectiveness of a vancomycin continuous infusion protocol within ICUs at a London tertiary-care hospital: a single-centre retrospective service evaluation 2022;4:dlac004.036. https://doi.org/10.1093/jacamr/dlac004.036
- Correction to: Improving adherence to and effectiveness of an adult critical care vancomycin continuous infusion protocol: a pilot quality improvement and administration data accuracy project. JAC Antimicrob Resist. 2023 Jun 8;5(3):dlad075. doi: 10.1093/jacamr/dlad075. eCollection 2023 Jun.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022.0286
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sepsis
-
University of Kansas Medical CenterUniversity of KansasRecruitingSepsis | Septic Shock | Sepsis Syndrome | Sepsis, Severe | Sepsis Bacterial | Sepsis BacteremiaUnited States
-
Jip GroenInBiomeRecruitingMicrobial Colonization | Neonatal Infection | Neonatal Sepsis, Early-Onset | Microbial Disease | Clinical Sepsis | Culture Negative Neonatal Sepsis | Neonatal Sepsis, Late-Onset | Culture Positive Neonatal SepsisNetherlands
-
The University of QueenslandRoyal Brisbane and Women's HospitalUnknown
-
Karolinska InstitutetÖrebro University, SwedenCompletedSepsis | Sepsis Syndrome | Sepsis, SevereSweden
-
Ohio State UniversityCompletedSepsis, Severe Sepsis and Septic ShockUnited States
-
Indonesia UniversityCompletedSevere Sepsis With Septic Shock | Severe Sepsis Without Septic ShockIndonesia
-
University of LeicesterUniversity Hospitals, Leicester; The Royal College of AnaesthetistsCompletedSepsis | Septic Shock | Severe Sepsis | Sepsis SyndromeUnited Kingdom
-
Beckman Coulter, Inc.Biomedical Advanced Research and Development AuthorityRecruitingSevere Sepsis | Severe Sepsis Without Septic ShockUnited States
-
Weill Medical College of Cornell UniversityNational Heart, Lung, and Blood Institute (NHLBI); New York Presbyterian Hospital and other collaboratorsCompletedSepsis | Septic Shock | Severe Sepsis | Infection | Sepsis SyndromeUnited States
-
Inverness Medical InnovationsCompletedSepsis | Systemic Inflammatory Response Syndrome | Severe Sepsis | Sepsis SyndromeUnited States
Clinical Trials on Drug Infusion Pump Monitoring
-
Far Eastern Memorial HospitalRecruitingHysteroscopic MyomectomyTaiwan
-
University of PittsburghCompleted
-
Far Eastern Memorial HospitalCompletedComplication of Surgical ProcedureTaiwan
-
Herrick Medical LLCUniversity of Southern CaliforniaRecruiting
-
Codman & ShurtleffTerminated
-
Oslo University HospitalUniversity of Oslo; University Hospital of North Norway; Haukeland University... and other collaboratorsActive, not recruitingUncontrolled HypertensionNorway
-
University of Texas Southwestern Medical CenterTerminatedCoronary Artery Disease | HypertensionUnited States
-
Seoul National University HospitalActive, not recruitingNutrition DisordersKorea, Republic of
-
Istanbul UniversityCompletedPerioperative Complication